Otsuka Holdings Co stock analysis
Want to see JP:4578 full AI Analyst Report?
Otsuka Holdings Co (4578) Stock Price & Analysis
4578 Stock Chart & Stats
- Day’s Range
- JPY 11,905.00 - JPY 12,170.00
- 52-Week Range
- JPY 8,150.00 - JPY 12,795.00
- Previous Close
- JPY 11,980.00
- Volume
- N/A
- Average Volume (3M)
- 1.17M
- Market Cap
- JPY 6.29T
- Enterprise Value
- JPY 5.87T
- Total Cash (Recent Filing)
- JPY 505.43B
- Total Debt (Recent Filing)
- JPY 191.49B
- Price to Earnings (P/E)
- 16.5
- Beta
- 0.67
- Next Earnings
- Feb 12, 2027 (Est.)
- EPS Estimate
- 108.09
- Next Dividend Ex-Date
- Dec 29, 2026
- Dividend Yield
- 1.41%
Bulls Say, Bears Say
Bulls Say
Improving Profitability
TTM margins show that the group is converting sales into substantial operating and bottom-line profit, while improvement from 2022–2023 indicates stronger earnings quality. Healthy profitability can support R&D, commercialization, and resilience over coming quarters.
Low Financial Leverage
Very low leverage gives Otsuka substantial financial flexibility relative to its equity base. This supports continued investment in drug development and consumer health products, while reducing the balance-sheet pressure associated with interest costs and refinancing needs.
Diversified Healthcare Platform
Exposure to both prescription medicines and branded consumer health products creates a broader healthcare platform than reliance on one product category alone. Global commercialization across these businesses provides multiple channels for durable revenue generation and product adoption.
Bears Say
Cooling Revenue Momentum
Slower recent revenue growth suggests that top-line momentum has moderated even while margins remain healthy. If this persists, it could limit operating leverage and make future profit expansion more dependent on efficiency, mix, or product performance.
Variable Cash Conversion
Positive free cash flow remains a strength, but weaker year-over-year generation and sub-one-times operating cash coverage show that reported earnings are not converting consistently into cash. Working-capital or timing effects could constrain funding flexibility over coming quarters.
Negative EPS Growth
Negative EPS growth indicates that per-share earnings momentum is weaker than the company’s margin profile alone suggests. Continued pressure would reduce the pace at which shareholder earnings compound and could make sustained profit improvement harder to demonstrate.
Otsuka Holdings Co News
4578 FAQ
What was Otsuka Holdings Co’s price range in the past 12 months?
What is Otsuka Holdings Co’s market cap?
When is Otsuka Holdings Co’s upcoming earnings report date?
How were Otsuka Holdings Co’s earnings last quarter?
Is Otsuka Holdings Co overvalued?
Does Otsuka Holdings Co pay dividends?
What is Otsuka Holdings Co’s EPS estimate?
How many shares outstanding does Otsuka Holdings Co have?
What happened to Otsuka Holdings Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Otsuka Holdings Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Otsuka Holdings Co
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Makoto Inoue
- Employees
- 37,758
- Website
- www.otsuka.com
- Address
- 2-9 Kanda-Tsukasamachi, Tokyo, TKY, 101-0048, JP
Otsuka Holdings Co (4578) Earnings & Revenues
4578 Company Deck
4578 Earnings Call
Earnings Call SentimentPositive
The earnings call highlighted strong growth in revenue and business profit, driven by pharmaceutical and nutraceutical segments. Forecasts have been revised upward, and there is an acquisition to further enhance drug discovery capabilities. However, there were some negatives, such as impairment losses and a decrease in certain revenues. Overall, the positive aspects significantly outweigh the negatives, indicating a strong performance and optimistic outlook.
View all JP:4578 earnings summaries4578 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 6 | 2 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 11 | 0 | 1 |
